Previous 10 | Next 10 |
Inventiva S.A. (IVA) Q4 2021 Earnings Conference Call March 08, 2022 08:00 AM ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer & Co-Founder Pierre Broqua - Chief Scientific Officer & Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier -...
Inventiva (NASDAQ:IVA) said the U.S. Food and Drug Administration (FDA) concluded that a phase 2 trial of the company's drug lanifibranor in combination empagliflozin to treat patients with non-cirrhotic NASH and Type 2 Diabetes (T2D) may proceed. The decision was made by the FDA after t...
Inventiva press release (NASDAQ:IVA): Q4 GAAP EPS of -€1.27. Revenue of €4.2M (+950.0% Y/Y). For further details see: Inventiva GAAP EPS of -€1.27, revenue of €4.2M
Inventiva (NASDAQ:IVA): 9M Revenue of €0.2M Cash and cash equivalents of €105.7M. Press Release For further details see: Inventiva reports Q3 results
Inventiva S.A. (IVA) Q2 2021 Results Conference Call September 21, 2021 08:00 AM ET Company Participants Frédéric Cren - Chairman, CEO and Co-Founder Pierre Broqua - CSO and Co-Founder Michael Cooreman - CMO Jean Volatier - CFO Conference Call Participants Lucy Codrington - Jefferie...
The following slide deck was published by Inventiva S.A. in conjunction with this event. For further details see: Inventiva (IVA) Investor Presentation - Slideshow
Gainers: Aptose Biosciences (APTO) +65%, Brainstorm Cell Therapeutics (BCLI) +13%, Prothena (PRTA) +12%, Armata Pharmaceuticals (ARMP) +8%, Inventiva (IVA) +8%.Losers: Benitec Biopharma (BNTC) -24%, Second Sight Medical Products (EYES) -1...
Inventiva S.A. (IVEVF) Q4 2020 Earnings Conference Call March 5, 2021 08:00 ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer and Co-Founder Pierre Broqua - Chief Scientific Officer and Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier - Chief...
The following slide deck was published by Inventiva S.A. in conjunction with this event. For further details see: Inventiva (IVEVF) Investor Presentation - Slideshow
Clinical-stage biopharmaceutical company Inventiva (IVA) announces the details of the Phase 3 trial evaluating its lead drug candidate lanifibranor in NASH following the end-of-Phase 2 meeting with the FDA.Non-alcoholic steatohepatitis ((NASH)), is a fatty liver disease due to obesity.As...
News, Short Squeeze, Breakout and More Instantly...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...